Skip to main content

Table 6 Current Combination Chemotherapy for Biliary tract cancer

From: A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

Author (published year) Number of Patients Species of cancer Regimen RR (%) MST (days) mTTF (days) Adverse effects (Gr3) Treatment related death
Ishii(2004) 21 GBca CEF(CDDP/5-FU/epirubicin) 33.3 177* - hematological toxicity (52.3%) none
  25 GBca FAM(5-FU/Doxorubicin/Mitomycin) 7.1   - hematological toxicity (20%) none
Lee (2004) 4 BDca Gemsitabine/CDDP 50 270 150 thrombocytopenia (75%) none
Doval(2004) 30 GBca Gemsitabine/CDDP 36.6 140 126 nausea/vomiting (16%) 2
Malik(2003) 11 GBca Gemsitabine/CDDP 64 294 196 anemia (45%) none
Knox (2004) 27 BDca/CBca Gemsitabine/5-FU 33 159 111 hematological toxicity (11%) none
Malik(2003) 30 CBca Leucovorin/5-FU 7.5 444 141 diarrhea (30%) 1
Kim (2003) 42 BDca/CBca Capesitabine/CDDP 21.4 273 111 leucopenia (20%) none
  1. (* The result was overall survival of combined CEF and FAM)
  2. Abbreveations
  3. BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, CDDP: Cisplatin, 5-FU: 5-fluorourasil, RR: response rate, MST: median survival time, mTTF: median time to treatment failure